---
document_datetime: 2025-09-25 16:45:28
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xaluprine-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: xaluprine-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.7729233
conversion_datetime: 2025-12-26 17:11:46.472651
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Xaluprine

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 24/09/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000300720                                       | variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            | PL                     |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
|                                                         | B.II.b.1 Replacement or addition of a manufacturingsiteforpartor allofthe manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging site -Accepted B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product-B.II.b.2.a Replacement or addition of a site where batch control/testing takes place -Accepted B.11.b.2Change toimporter,batchrelease arrangements and quality control testing of the finished product-B.II.b.2.a Replacementoradditionofasitewhere batch control/testing takes place -Accepted B.II.b.2.cReplacement or additionof a manufacturer responsiblefor importation and/or batch release-B.I1.b.2.c.1 Not |            |            |                        |
| Marketing Authorisation Transfer - H / EMA/T/0000287233 | -Transferofamarketingauthorisation transfer ofmarketing authorisationfrom NovaLaboratoriesIreland Limited to Lipomed GmbH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 24/07/2025 | 11/08/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000254018   | 18/03/2025   | N/A   |
|-----------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

| administration device - B.IV.1.z Other variation - Accepted   |
|---------------------------------------------------------------|